Tonix Pharmaceuticals, Inc.
Registry sponsor category
Industry
- Other names
- Tonix Pharmaceuticals, Inc.
- Company name
- Tonix Pharmaceuticals, Inc.
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Website
- http://www.tonixpharma.com
- Publicly traded (proxy)
- No
- Listing at source
- Listed
- Wikidata ID
- Q39052499
Related records
Trials (39)
- (TNX-1500) in Kidney Transplant Recipients
- 12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients
- 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
- A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
- A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
- A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults.
- A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects
- A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
- A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
- A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
- A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia
- A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects
- A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
- A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
- A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine
- A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
- An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) Subjects
- Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens
- BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)